Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval. (BioWorld Today)
Alteon Inc. voluntarily suspended enrollment in its ongoing Phase II trials of alagebrium after preclinical data indicated high doses of the therapy could be associated with liver cell alterations and tumors. (BioWorld Today)
Although it had plenty of money in the bank, Idun Pharmaceuticals Inc. made a strategic decision to become part of a big pharmaceutical company that will help advance its lead liver disease product. (BioWorld Today)
With an FDA nod for its vaccinia immune globulin, DVC LLC will provide the U.S. military with a product addressing the serious side effects of the smallpox vaccine. (BioWorld Today)
Aphton Corp.'s stock fell more than 45 percent Tuesday following news that its lead pancreatic cancer drug, Insegia, failed to meet the primary endpoint in a Phase III trial. (BioWorld Today)
Encysive Pharmaceuticals Inc. plans to file a new drug application in April based on pivotal Phase III data showing that Thelin met its primary endpoint in pulmonary arterial hypertension. (BioWorld Today)
